This indicates that the key N501Y mutation, which is found in the emerging U.K and South Africa variants, does not create resistance to the Pfizer-BioNTech vaccine induced immune responses.

Approved for Ages 12 and Up The Pfizer/BioNTech vaccine is currently approved for people 12 and older in South Africa. Pfizer is expecting trial data for children as young as 6 months “as soon ...

Introducing Life Uncensored; an interactive platform, specially created to provide a more human approach to medical conditions such as erectile dysfunction (ED), contraception and menopause (Pfizer ...

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Pfizer said Friday that a clinical trial ... of the data looked at numbers from 1,219 adults in North and South America, Europe, Africa and Asia. Several companies are working on so-called oral ...

Data from a real-world study South Africa has indicated that the Omicron ... Top of the list is that while two doses of the Pfizer/BioNTech Comirnaty vaccine only seems to provide 33% protection ...